Search

Displaying results 2711 - 2720 of 8974 in total
  1. Drug

    Flurpiridaz F-18

    go.drugbank.com/drugs/DB18773
    Approved

    Flurpiridaz F-18 is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI), which is an imaging process used in patients with known or suspected

  2. Drug

    Talquetamab

    go.drugbank.com/drugs/DB16678
    ApprovedInvestigational

    [A260890] The Committee for Medicinal Products for Human Use (CHMP) of the EMA recommended conditional marketing authorization for talquetamab for the treatment of relapsed or refractory multiple myeloma … It works to recruit CD3-expressing T cells to GPRC5D-expressing multiple myeloma cells to induce T-cell–mediated cytotoxicity.

  3. Drug

    Crotalus adamanteus antivenin

    go.drugbank.com/drugs/DB13893
    Approved

    It is intravenously administered to limit systemic toxicity [FDA label]. … The majority of people bitten are males and about 50% occur in the age group of 18 to 28 [F116].

  4. Drug

    Dextrothyroxine

    go.drugbank.com/drugs/DB00509
    ApprovedWithdrawn

    Thyroxine is peripherally deiodinated to form triiodothyronine which exerts a broad spectrum of stimulatory effects on cell metabolism. … Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood.

    Synonyms: O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-D-tyrosine
  5. Drug

    Dolasetron

    go.drugbank.com/drugs/DB00757
    ApprovedInvestigational

    This drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors. … Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  6. Drug

    Ferric pyrophosphate

    go.drugbank.com/drugs/DB09147
    ApprovedInvestigational

    The ferric ion is strongly complexed by pyrophosphate.[A31979] It presents an increasing interest as this insoluble form can be milder in the gastrointestinal tract and present higher bioavailability.

  7. Drug

    Sipuleucel-T

    go.drugbank.com/drugs/DB06688
    ApprovedInvestigational

    The treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014. … Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer.

    Categories: sipuleucel-TSynonyms: Sipuleucel-T
  8. Drug

    Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen

    go.drugbank.com/drugs/DB10285
    ApprovedInvestigational

    Neisseria meningitidis serogroup b recombinant lp2086 b01 protein variant antigen is a sterile vaccine for intramuscular injection indicated for the active immunization to prevent invasive disease caused … by *Neisseria meningitidis* serogroup B.

    Mixtures: TRUMENBA SUSPENSION FOR INJECTION IN SINGLE-DOSE PRE-FILLED SYRINGE 0.5ML
  9. Drug

    Vimseltinib

    go.drugbank.com/drugs/DB17520
    ApprovedInvestigational

    [L52230,A265035] Vimseltinib - under the brand name Romvimza - was approved by the FDA in February 2025 for the treatment of tenosynovial giant cell tumours for which surgical resection is not appropriate … [A265035] It is intended to provide a safer alternative to [pexidartinib], a previously approved CSF1R inhibitor associated with significant liver toxicity - the greater selectivity of vimseltinib results

  10. Drug

    Sorafenib

    go.drugbank.com/drugs/DB00398
    ApprovedInvestigational

    [A255852] First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma